Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial.
Niemeyer-van der Kolk T, Buters TP, Krouwels L, Boltjes J, de Kam ML, van der Wall H, van Alewijk DCJG, van den Munckhof EHA, Becker MJ, Feiss G, Florencia EF, Prens EP, Moerland M, Burggraaf J, Rissmann R, van Doorn MBA.
Niemeyer-van der Kolk T, et al. Among authors: burggraaf j.
J Am Acad Dermatol. 2022 Apr;86(4):854-862. doi: 10.1016/j.jaad.2020.08.132. Epub 2020 Oct 1.
J Am Acad Dermatol. 2022.
PMID: 33010325
Clinical Trial.